For investors seeking momentum, State Street SPDR S&P Biotech ETF XBI is probably on the radar. The fund just hit a 52-week high and has risen 98.15% from its 52-week low price of $66.66/share. But ...

Although the equities market often embodies chaos and capricious non-linearity, few sectors witness as much kinetic wildness like biotechnology. At its core, biotech represents an innovative push ...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one ...

The iShares Biotechnology ETF offers diversified exposure to the biotech sector, focusing on large-cap leaders while maintaining positions in smaller innovators. IBB is cap-weighted and top-heavy, ...

Biopharma has finally begun catching up with the overall stock market, if the positive returns shown by the top three exchange traded funds (ETFs) since the spring are any indication. Faring best of ...

FBT returned 29% over the past year and gained 5.4% in the first week of 2026. Federal Reserve officials forecast another 150 basis points of rate cuts in 2026. Healthcare stocks trade at some of the ...

Active exchange-traded funds captured more fresh inflows through the first three quarters of 2025 than in any other previous full year. They’ve pulled in $338 billion so far; more than 2021, 2022, and ...

The average expense ratio for passively managed exchange-traded funds is 0.14%, and for actively managed ETFs, it's 0.44%, according to Morningstar Direct. While low fees are important because the ...

Forbes contributors publish independent expert analyses and insights. I'm a journalist who covers finance and investing. Nov 29, 2025, 05:01pm EST Global ETF asset growth as at end of September 2025.